Compare · PRCT vs RMD
PRCT vs RMD
Side-by-side comparison of PROCEPT BioRobotics Corporation (PRCT) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PRCT and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $34.13B, about 27.6x PRCT ($1.24B).
- PRCT has been more active in the news (11 items in the past 4 weeks vs 9 for RMD).
- Both have 25 recent analyst ratings on file.
- Company
- PROCEPT BioRobotics Corporation
- ResMed Inc.
- Price
- -
- -
- Market cap
- $1.24B
- $34.13B
- 1M return
- -
- +16.50%
- 1Y return
- -
- -17.04%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 11
- 9
- Recent ratings
- 25
- 25
PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest PRCT
- PROCEPT BioRobotics® to Attend the Baird 2026 Global Healthcare Conference on September 15, 2026
- EVP, Chief Technology Officer Templin Barry L was granted 26,246 shares, increasing direct ownership by 38% to 95,199 units (SEC Form 4)
- EVP, CLO, CORP. SEC. Nouri Alaleh was granted 22,965 shares, increasing direct ownership by 22% to 128,034 units (SEC Form 4)
- EVP, CFO Waters Kevin was granted 29,527 shares, increasing direct ownership by 20% to 180,728 units (SEC Form 4)
- Chief Strat/Marketing Officer Sharma Pooja was granted 23,622 shares, increasing direct ownership by 27% to 111,181 units (SEC Form 4)
- President, CEO Wood Larry L bought $498,315 worth of shares (23,900 units at $20.85) (SEC Form 4)
- SEC Form 10-Q filed by PROCEPT BioRobotics Corporation
- PROCEPT BioRobotics downgraded by William Blair
- PROCEPT BioRobotics downgraded by Wells Fargo with a new price target
- PROCEPT BioRobotics Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest RMD
- 23XI Racing NASCAR Driver Tyler Reddick Reveals Sleep Apnea Diagnosis, Teams Up with Resmed to Help Others Recognize the Signs
- Rothschild & Co Redburn initiated coverage on ResMed with a new price target
- SEC Form 8-K filed by ResMed Inc.
- Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor
- SEC Form 10-K filed by ResMed Inc.
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,026,596 worth of ResMed Common Stock (4,991 units at $205.69) as part of a pre-agreed trading plan (SEC Form 4)
- ResMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026
- Director Farrell Peter C sold $1,800,000 worth of ResMed Common Stock (8,000 units at $225.00) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 52,773 units (SEC Form 4)
- BetterInvesting™ Magazine Update on Broadridge Financial Resources Inc. (NYSE:BR) and ResMed Inc. (NYSE:RMD)